315 related articles for article (PubMed ID: 32554756)
1. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.
Patel SD; Bono TR; Rowe SM; Solomon GM
Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32554756
[TBL] [Abstract][Full Text] [Related]
2. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
Shi J; Li H; Yuan C; Luo M; Wei J; Liu X
Oxid Med Cell Longev; 2018; 2018():6567578. PubMed ID: 29849907
[TBL] [Abstract][Full Text] [Related]
3. CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD.
Martinez-Garcia MA; Sierra-Párraga JM; Quintana E; López-Campos JL
J Cyst Fibros; 2022 Sep; 21(5):741-744. PubMed ID: 35551858
[No Abstract] [Full Text] [Related]
4. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Cantin AM
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S150-5. PubMed ID: 27115950
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.
Mall MA; Criner GJ; Miravitlles M; Rowe SM; Vogelmeier CF; Rowlands DJ; Schoenberger M; Altman P
Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 37003609
[TBL] [Abstract][Full Text] [Related]
6. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
[TBL] [Abstract][Full Text] [Related]
7. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
8. Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.
Raju SV; Solomon GM; Dransfield MT; Rowe SM
Clin Chest Med; 2016 Mar; 37(1):147-58. PubMed ID: 26857776
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction.
Rasmussen JE; Sheridan JT; Polk W; Davies CM; Tarran R
J Biol Chem; 2014 Mar; 289(11):7671-81. PubMed ID: 24448802
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
Perrem L; Ratjen F
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
[TBL] [Abstract][Full Text] [Related]
11. Unified Airway-Cystic Fibrosis.
Cho DY; Grayson JW; Woodworth BA
Otolaryngol Clin North Am; 2023 Feb; 56(1):125-136. PubMed ID: 36266104
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
Kaza N; Lin VY; Stanford D; Hussain SS; Falk Libby E; Kim H; Borgonovi M; Conrath K; Mutyam V; Byzek SA; Tang LP; Trombley JE; Rasmussen L; Schoeb T; Leung HM; Tearney GJ; Raju SV; Rowe SM
Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34916262
[TBL] [Abstract][Full Text] [Related]
13. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.
Sloane PA; Shastry S; Wilhelm A; Courville C; Tang LP; Backer K; Levin E; Raju SV; Li Y; Mazur M; Byan-Parker S; Grizzle W; Sorscher EJ; Dransfield MT; Rowe SM
PLoS One; 2012; 7(6):e39809. PubMed ID: 22768130
[TBL] [Abstract][Full Text] [Related]
14. Rapid therapeutic advances in CFTR modulator science.
Clancy JP
Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
[TBL] [Abstract][Full Text] [Related]
15. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Mall MA
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
[TBL] [Abstract][Full Text] [Related]
16. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.
Dransfield MT; Wilhelm AM; Flanagan B; Courville C; Tidwell SL; Raju SV; Gaggar A; Steele C; Tang LP; Liu B; Rowe SM
Chest; 2013 Aug; 144(2):498-506. PubMed ID: 23538783
[TBL] [Abstract][Full Text] [Related]
17. Cigarette smoke and CFTR: implications in the pathogenesis of COPD.
Rab A; Rowe SM; Raju SV; Bebok Z; Matalon S; Collawn JF
Am J Physiol Lung Cell Mol Physiol; 2013 Oct; 305(8):L530-41. PubMed ID: 23934925
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function.
Bodas M; Silverberg D; Walworth K; Brucia K; Vij N
Antioxid Redox Signal; 2017 Sep; 27(7):433-451. PubMed ID: 28006950
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.
Solomon GM; Raju SV; Dransfield MT; Rowe SM
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2(Suppl 2):S169-76. PubMed ID: 27115953
[TBL] [Abstract][Full Text] [Related]
20. Potential systemic effects of acquired CFTR dysfunction in COPD.
Miravitlles M; Criner GJ; Mall MA; Rowe SM; Vogelmeier CF; Hederer B; Schoenberger M; Altman P
Respir Med; 2024 Jan; 221():107499. PubMed ID: 38104786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
